Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...

Beyond cancer treatments, scans, and countless appointments, there is another critical factor in a patient’s well-being: ...

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship ...

Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

Nurses are vital experts to the multidisciplinary oncology team who continue to expand their role in meeting the needs of ...